NHS INDUSTRIES - NHS CSE - NNHHF OTC
CANNABIS RESEARCH TREATING LUNG CANCER WITH CANNABIS CANNABINOIDS ENHANCING THERAPEUTIC EFFICACY |
| These
shares have moved up nicely on their aggressive approach
towards cancer applications . In association with the
Harvard Medical School this company intends
to peruse all avenues available According to the World Health Organization, up to 80 percent of the populations in the world use medicinal plants as remedies. Recently, over 33 U.S. states and a growing number of countries have legalized medical cannabis. The National Institutes of Health and World Health Organization encourage research on medical cannabis for treating cancer, the side effects of radiotherapy or chemotherapy and treatment of other diseases, including pain, neurological disorders and so forth. Besides cannabis, it is estimated that of the 300,000 plant species that exist in the world, only 15 percent have been evaluated to determine their pharmacological potential. We urge all serious investors to place these shares on their BUY LIST |
|
|
Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading InstitutionsIRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (OTC: NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP). READ MORE
|